Javascript must be enabled to continue!
Abstract 1778: MALAT1 and TUG1 long non-coding RNAs signalling mechanisms in response to SRPK1 inhibitor in prostate cancer
View through CrossRef
Abstract
Introduction:
Prostate cancer (PCa) is a leading cause of cancer death, and there are significant racial disparities in patient outcomes. Non-coding RNAs (lncRNAs) MALAT1 and TUG1 are recognised for their roles in oncogenic pathways. Their precise interacting mechanisms with splicing factors and splicing factor kinases is understudied.
Aim:
This study aims to map the biological pathways influenced by TUG1, MALAT1 in response to SRPK1 inhibitor prostate cancer cells
Materials and Methods:
Bioinformatics tools LncSEA 2.0, STRING, DAVID and Reactome were used to analyse the interactions between MALAT1, TUG1 and relevant miRNAs and their target genes. Resozuring cell viability assay was used to measure PCa cell viability (PC-3 cells vs HEK) in response to Sphinx31 at 24hrs and 48hrs. Next, RT-qPCR was used to measure gene expression levels of the lncRNAs.
Results and Discussion:
MALAT1 and TUG1 act as competing endogenous RNAs (ceRNAs) to sponge miRNAs that regulate critical tumour proliferation and migration genes, including PTEN and BCL2. SRPK1 regulates splicing factors to enhance tumour aggressiveness. The MALAT1-miR-125b-BCL2 and TUG1-miR-29b-PTEN axes are critical pathways for PCa progression, especially in advanced stages. Sphinx31 is cytotoxic in a time dependent manner to the PCa cells, while the 2 lncRNAs expression is elevated in PCa cells prior to Sphinx31 treatment.
Conclusion:
Targeting lncRNA-miRNA networks and splicing factor interactions, especially MALAT1 and SRPK1, is a potential therapeutic target for PCa.
Citation Format:
Linomtha Gabada, Zodwa Dlamini, Rahaba Makgotso Marima. MALAT1 and TUG1 long non-coding RNAs signalling mechanisms in response to SRPK1 inhibitor in prostate cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 1778.
American Association for Cancer Research (AACR)
Title: Abstract 1778: MALAT1 and TUG1 long non-coding RNAs signalling mechanisms in response to SRPK1 inhibitor in prostate cancer
Description:
Abstract
Introduction:
Prostate cancer (PCa) is a leading cause of cancer death, and there are significant racial disparities in patient outcomes.
Non-coding RNAs (lncRNAs) MALAT1 and TUG1 are recognised for their roles in oncogenic pathways.
Their precise interacting mechanisms with splicing factors and splicing factor kinases is understudied.
Aim:
This study aims to map the biological pathways influenced by TUG1, MALAT1 in response to SRPK1 inhibitor prostate cancer cells
Materials and Methods:
Bioinformatics tools LncSEA 2.
0, STRING, DAVID and Reactome were used to analyse the interactions between MALAT1, TUG1 and relevant miRNAs and their target genes.
Resozuring cell viability assay was used to measure PCa cell viability (PC-3 cells vs HEK) in response to Sphinx31 at 24hrs and 48hrs.
Next, RT-qPCR was used to measure gene expression levels of the lncRNAs.
Results and Discussion:
MALAT1 and TUG1 act as competing endogenous RNAs (ceRNAs) to sponge miRNAs that regulate critical tumour proliferation and migration genes, including PTEN and BCL2.
SRPK1 regulates splicing factors to enhance tumour aggressiveness.
The MALAT1-miR-125b-BCL2 and TUG1-miR-29b-PTEN axes are critical pathways for PCa progression, especially in advanced stages.
Sphinx31 is cytotoxic in a time dependent manner to the PCa cells, while the 2 lncRNAs expression is elevated in PCa cells prior to Sphinx31 treatment.
Conclusion:
Targeting lncRNA-miRNA networks and splicing factor interactions, especially MALAT1 and SRPK1, is a potential therapeutic target for PCa.
Citation Format:
Linomtha Gabada, Zodwa Dlamini, Rahaba Makgotso Marima.
MALAT1 and TUG1 long non-coding RNAs signalling mechanisms in response to SRPK1 inhibitor in prostate cancer [abstract].
In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL.
Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 1778.
Related Results
Abstract 4400: SRPK1: The dominant power of alternative splicing in tumor chemoresistance
Abstract 4400: SRPK1: The dominant power of alternative splicing in tumor chemoresistance
Abstract
Introduction:
Abnormal pre-mRNA alternative splicing (AS) is critical in shaping tumor chemoresistance by modulating th...
Abstract 1835: NFATC1 regulates the long non-coding RNA MALAT1 in breast cancer
Abstract 1835: NFATC1 regulates the long non-coding RNA MALAT1 in breast cancer
Abstract
Metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) is a long non-coding RNA overexpressed in many solid tumors such as breast, colorectal, live...
Pathophysiological Functions of the lncRNA TUG1
Pathophysiological Functions of the lncRNA TUG1
Background:
Long non-coding RNAs (lncRNAs) with little or no coding capacity are associated with
a plethora of cellular functions, participating in various biological processes. Cu...
Data from Cancer-Specific Targeting of Taurine-Upregulated Gene 1 Enhances the Effects of Chemotherapy in Pancreatic Cancer
Data from Cancer-Specific Targeting of Taurine-Upregulated Gene 1 Enhances the Effects of Chemotherapy in Pancreatic Cancer
<div>Abstract<p>Overcoming drug resistance is one of the biggest challenges in cancer chemotherapy. In this study, we examine whether targeting the long noncoding RNA t...
Abstract 1825: The inhibitory effect of long non-coding RNA MALAT1 on Smads signaling pathway.
Abstract 1825: The inhibitory effect of long non-coding RNA MALAT1 on Smads signaling pathway.
Abstract
Long non-coding RNA (lncRNA) is arbitrarily defined as RNA longer than 200 bases that does not encode mRNA, rRNA or tRNA. LncRNAs are involved in almost eve...
Cellular proliferation of Hemangioma endothelial cells (HemECs) under targeted regulation of LncRNA MALAT1 via miR-494-3p/PTEN Axis
Cellular proliferation of Hemangioma endothelial cells (HemECs) under targeted regulation of LncRNA MALAT1 via miR-494-3p/PTEN Axis
The current study is aimed to explore the regulation of lncRNA MALAT1 in human HemECs functions. In our study, relative expressions of MALAT1, miR-494-3p and PTEN in HemECs (HemEC)...
LncRNA TUG1 is upregulated and promotes cell proliferation in osteosarcoma
LncRNA TUG1 is upregulated and promotes cell proliferation in osteosarcoma
Abstract
Objective: To examine the expression and function of long non-coding RNA taurine up-regulated 1 (TUG1) in human osteosarcoma cells. Methods: Real-time quant...
Long non-coding RNA taurine upregulated gene 1 is downregulated in osteoporosis and influences the osteogenic differentiation of bone marrow mesenchymal stem cells
Long non-coding RNA taurine upregulated gene 1 is downregulated in osteoporosis and influences the osteogenic differentiation of bone marrow mesenchymal stem cells
Background
With aging, an imbalance in bone remodeling leading to increased bone resorption and decreased bone formation is thought to contribute to osteoporosis. Os...

